Kier K L, Pathak D S
College of Pharmacy, Ohio Northern University, Ada.
Top Hosp Pharm Manage. 1991 Apr;11(1):9-15.
The use of outcome assessment with DUE can provide more detailed information on the impact of drug therapy on the overall health status of the patient, rather than just the narrow view of the drug-prescribing process within the institution. These studies may justify additional pharmacists to help in the selection of drugs and their potential to affect overall quality patient care. In addition, the Joint Commission is recommending that measurement of health outcomes is important in QA. The Joint Commission has stated in their Agenda for Change program "that patient outcomes are influenced by all activities of a health care program." The Joint Commission plans to develop standards that "describe in functional terms what the key jobs are that need to be done to produce good patient outcomes." The major problem with adding outcome measures in the assessment of DUE programs is the evolutionary nature of the available technology to measure these patient outcomes. Incorporation of outcome measures into DUE programs can provide measures of the impact of drug therapy on the patients' HQOL. This HQOL is potentially a better reflection of patient outcomes and the assessment of quality of care.
使用药物利用评价（DUE）进行结果评估，可以提供关于药物治疗对患者整体健康状况影响的更详细信息，而不仅仅是机构内药物处方过程的狭隘视角。这些研究可能证明需要更多药剂师来协助药物选择及其对患者整体护理质量的潜在影响。此外，联合委员会建议在质量保证（QA）中测量健康结果很重要。联合委员会在其“变革议程”计划中指出，“患者结果受医疗保健计划的所有活动影响”。联合委员会计划制定标准，“从功能角度描述为产生良好患者结果需要完成的关键工作”。在DUE计划评估中增加结果测量的主要问题是用于测量这些患者结果的现有技术的不断发展性质。将结果测量纳入DUE计划可以提供药物治疗对患者健康相关生活质量（HQOL）影响的测量。这种HQOL可能更好地反映患者结果和护理质量评估。
